Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches

April 22, 2014
Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches
Dr. Jeffrey Zigman (left), Angela K. Walker, and their colleagues, identified new anti-depressant mechanisms and therapeutic approaches to treating depression. Credit: UT Southwestern

Researchers at UT Southwestern Medical Center are making breakthroughs that could benefit people suffering from depression.

A team of physician-scientists at UT Southwestern has identified a major mechanism by which (a hormone with natural anti-depressant properties) works inside the brain. Simultaneously, the researchers identified a potentially powerful new treatment for in the form of a neuroprotective drug known as P7C3.

The study, published online in April's issue of Molecular Psychiatry, is notable because although a number of anti-depressant drugs and other treatments are available, an estimated one in 10 adults in the U.S. still report depression, according to the Centers for Disease Control and Prevention.

"By investigating the way the so-called 'hunger hormone' ghrelin works to limit the extent of depression following long-term exposure to stress, we discovered what could become a brand new class of anti-depressant drugs," said Dr. Jeffrey Zigman, Associate Professor of Internal Medicine and Psychiatry at UT Southwestern, and co-senior author of the study.

Ghrelin, a hormone produced in the stomach and intestines, has several widely known functions, including the ability to stimulate appetite. The latest research builds on a 2008 study led by Dr. Zigman, in which the team discovered that ghrelin exhibited natural anti-depressant effects that manifest when its levels rise as a result of caloric restriction or prolonged psychological stress.

The current findings identify ghrelin's ability to stimulate adult hippocampal neurogenesis, the formation of new neurons, in animal models. In addition, Dr. Zigman and his colleagues also found that the regenerative process inside the hippocampus – a region of the brain that regulates mood, memory, and complex eating behaviors – is crucial in limiting the severity of depression following prolonged exposure to stress.

"After identifying the mechanism of ghrelin's anti-depressant actions, we investigated whether increasing this ghrelin effect by directly enhancing hippocampal neurogenesis with the recently reported P7C3 class of neuroprotective compounds would result in even greater anti-depressant behavioral effects," Dr. Zigman said.

The P7C3 compounds were discovered in 2010 by a team of UT Southwestern researchers led by Dr. Steven McKnight, Chair of Biochemistry, Dr. Joseph Ready, Professor of Biochemistry, and Dr. Andrew Pieper, a former UT Southwestern faculty member and co-senior author of the current study. Previous research demonstrated P7C3's promising neuroprotective abilities in instances of Parkinson's disease, amyotrophic lateral sclerosis (ALS), and traumatic brain injury. Today, researchers hope that it can have a transformative impact on depression treatment too.

"We found that P7C3 exerted a potent anti-depressant effect via its neurogenesis-promoting properties," said Dr. Pieper, who is now Associate Professor of Neurology and Psychiatry at the University of Iowa Carver College of Medicine. "Also exciting, a highly active P7C3 analog was able to quickly enhance neurogenesis to a much greater level than a wide spectrum of currently marketed anti-depressant drugs."

Based on the study's behavioral findings, researchers believe that individuals with depression associated with chronic stress or with altered ghrelin levels or ghrelin resistance, as has been described or theorized for conditions such as obesity and anorexia nervosa, might be particularly responsive to treatment with highly neuroprotective drugs, such as the P7C3 compounds.

Future studies will examine the ability to apply these findings to other forms of depression, including the possibility of developing clinical trials aimed at identifying whether or not P7C3 compounds have anti-depressant effects in people with major depression, as predicted. The three main types of depressive disorders include major depression, dysthymia, and bipolar disorder.

Explore further: Ghrelin likely involved in why we choose 'comfort foods' when stressed

Related Stories

Nasal spray delivers new type of depression treatment

March 24, 2014

A nasal spray that delivers a peptide to treat depression holds promise as a potential alternative therapeutic approach, research from the Centre for Addiction and Mental Health (CAMH) shows. The study, led by CAMH's Dr. ...

New target for developing effective anti-depressants

April 12, 2011

For the first time in a human model, scientists have discovered how anti-depressants make new brain cells. This means that researchers can now develop better and more efficient drugs to combat depression.

Is depression over-diagnosed and over-treated?

January 8, 2014

(Medical Xpress)—A University of Liverpool study has found that people are increasingly diagnosed and treated with medication for depression when they are suffering 'normal' human experiences such as grief and sadness.

Recommended for you

Where belief in free will is linked to happiness

January 23, 2017

Western and Asian cultures tend to have different core beliefs around free will. In a recent study published in Frontiers in Psychology, Jingguang Li, professor at Dali University, and his research team show the link between ...

Study reveals areas of the brain impacted by PTSD

January 23, 2017

Researchers at Boston University School of Medicine (BUSM) and the VA Boston Healthcare System are one step closer to understanding the specific nature of brain changes associated with Posttraumatic Stress Disorder (PTSD).

For health and happiness, share good news

January 22, 2017

Service members, including both active and recently separated, have been called upon to fight overseas and to assist during natural disasters at home. They can face unique challenges when they return in both the workplace ...

The great unknown—risk-taking behaviour in adolescents

January 19, 2017

Adolescents are more likely to ignore information that could prompt them to rethink risky decisions. This may explain why information campaigns on risky behaviors such as drug abuse tend to have only limited success. These ...

Mandarin makes you more musical?

January 18, 2017

Mandarin makes you more musical - and at a much earlier age than previously thought. That's the suggestion of a new study from the University of California San Diego. But hold on there, overachiever parents, don't' rush just ...


Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (3) Apr 22, 2014
Have any of you tried's Empowerplus supplement? They say it greatly reduces depression through micronutrient treatment to the brain. It's backed up by tons of scientific studies. I'd love to hear from anyone who's actually tried it.
Lex Talonis
2.3 / 5 (3) Apr 23, 2014
I'd love to see a report that is not funded by arseholes in the American drug industry.

Considering depression is easily cured by diet, exercise, changing the attitude, and going and mixing with people who are not idiots.....

And making yourself develop a few interests - and enjoying them.

Thinking of someone else, besides your self, for a change, is usually a good thing too.

Fucking American drug pushers......
5 / 5 (3) Apr 23, 2014
Considering depression is easily cured by diet, exercise, changing the attitude, and going and mixing with people who are not idiots.....

Nope. I've tried all that, good diet, good sleep, exercise every day, therapist. Like current drugs, they do little. Depression is a neurobiological disease that will be most successfully treated by newer, better generations of drugs into the future. As the article states, the disruption of hippocampal neurogenesis due to high amounts of stress is a cause of depression and reversing that process is looking like a very promising avenue right now. None of the current drugs really target that problem specifically or strongly, and I strongly disapprove of dozens of Prozac-like compounds being created which are only incrementally better, but that doesn't mean cutting-edge research from academia should be put in the same category as big Pharma.
Lex Talonis
1 / 5 (2) Apr 24, 2014

Shrewed but transparent - so which drug company pays your wages to spread this propaganda?

Your either stupid or dishonest. So which is it?
not rated yet Apr 27, 2014
Lex_T, you cruelly confuse the two major types of depression.

'Reactive' *may* respond to counselling, changes in diet, habit, exercise etc. 'Endogenous' will not. Trying to treat that as 'Reactive' is as futile as praying over a young 'Type 1' diabetic who really, really needs an insulin injection...

Just to confuse matters, an 'Endogenous' depression may provoke an additional 'Reactive' response. Good luck teasing their overlapping symptoms apart...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.